Integrated BioPharma, Inc.
INBP · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $54 | $50 | $51 | $56 |
| % Growth | 8% | -0.7% | -9.9% | – |
| Cost of Goods Sold | $49 | $46 | $47 | $50 |
| Gross Profit | $6 | $4 | $4 | $7 |
| % Margin | 10.2% | 7.7% | 8% | 11.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $4 | $4 | $4 |
| Operating Income | $2 | $0 | $0 | $2 |
| % Margin | 3.7% | 0.5% | 0.2% | 3.5% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | $2 | $0 | $0 | $3 |
| Tax Expense | $1 | $0 | $0 | -$1 |
| Net Income | $1 | $0 | -$0 | $4 |
| % Margin | 1.5% | 0.2% | -0.1% | 6.8% |
| EPS | 0.027 | 0.004 | -0.001 | 0.13 |
| % Growth | 621.6% | 436.4% | -100.8% | – |
| EPS Diluted | 0.026 | 0.004 | -0.001 | 0.12 |
| Weighted Avg Shares Out | 30 | 30 | 30 | 30 |
| Weighted Avg Shares Out Dil | 31 | 31 | 30 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $3 | $1 | $1 | $4 |
| % Margin | 6.2% | 2.9% | 2.5% | 6.3% |